Mr. Young manages the Firm and is actively involved in client transactions and financings. Under his leadership, Young & Partners has established and maintained its position as a leader in the industry. Prior to 1996, Mr. Young was Global Head of Chemicals Investment Banking at Lehman Brothers where he oversaw the worldwide efforts of Lehman in Chemicals. Previously he was head of the Chemical Groups at Salomon Brothers and Schroders. Mr. Young has been involved with the chemical and pharma industries for over twenty four years. Early in his career while with Bain & Co., Mr. Young provided strategic advice to major chemical and life science companies.
Mr. Young has been a financial advisor to a wide variety of leading chemical and pharmaceutical companies globally with regard to mergers, acquisitions, restructurings and capital raising. Some of his current and past clients include Air Products, AlliedSignal/Honeywell, Arch Chemicals, Aristech, Bayer, Caliper Life Sciences, Celanese, Chirex, Codexis, Degussa, Dow Reichhold Specialty Latex, DSM, DuPont, Eastman Chemical, GAF/International Specialty Products, Henkel, Lilly Industries, Medicus Pharmaceutical, Minerals Technologies, Mitsubishi, Mitsui, Monsanto, NL Industries, ÖMV/Chemie Linz, Perkin-Elmer, Oxiteno/Ultrapar, Philipp Brothers Chemicals, PQ Corporation, PureTec Corporation, Reichhold, Reilly Industries, Rexene, Rhône-Poulenc/Rhodia, Rütgers, Shell, Solutia, Sterling Chemicals, Sybron Chemicals, Synthon Chiragenics, TETRA Technologies, Thai Petrochemical, Troy Chemical, UOP, Wellman and Witco.
Mr. Young received an M.B.A. from the Harvard Business School (Baker Scholar with Highest Distinction), an M.S. in Accounting from the New York University and a B.A. in Economics from Yale University. He is a Certified Public Accountant and member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants. Mr. Young is a board member of Société de Chimie Industrielle - American Section, a chemical and pharmaceutical industry association and on the Editorial Advisory Board of Pharmaceutical Executive Magazine. He was also the recipient of the 2006 Commercial Development and Marketing Association Executive Excellence award at an award dinner in April 2006.
Steve has extensive M&A advisory, valuation and financing experience in the petrochemical, specialty chemical and fertilizer sectors. Prior to joining Young & Partners, Steve was a Managing Director and Co-Head of the Global Chemicals and Fertilizers group at Morgan Stanley & Co. with responsibility for North and South America, Japan and Asia.
Steve joined Morgan Stanley in 1991 as a financial analyst in the Financial Sponsor Group and was promoted to Investment Banking Associate in 1994. He joined the chemicals group in 1995 where he covered North and South American commodity chemical and fertilizer clients. In 2001, he was promoted to Executive Director and became Chief Operating Officer for Morgan Stanley's Global Corporate Finance Department. In 2004, he assumed client coverage responsibilities again as Co-Head of Morgan Stanley's Global Chemicals and Fertilizers Group.
Some of his current and past clients include Agrium, Air Products, ARCO Chemical, Aristech, Borden Chemical, BP Chemicals, Cambrex, Celanese, CF Industries, Chemtura, Dow Chemical, DuPont, Elemica, Equate, Great Lakes Chemical, Grupo Ultra, Intrepid Potash, Kraton Polymers, Lyondell Chemical, Petroquimica Colombiana, Rhodia-Ster, Resolution Performance Products, Union Carbide, Uniroyal Chemical, UOP, Wellman and Westlake Chemical.
Mr. Floyd received an ScB in Chemical Engineering from Brown University and is a member of Tau Beta Pi.
Mr. Guggenheimer has extensive M&A advisory experience in the biopharmaceutical, medical technology and diagnostics sectors. Prior to joining Young & Partners, Randy was a Managing Director and Co-Head of Healthcare Mergers & Acquisitions at Lehman Brothers and was a Managing Director at Dresdner Kleinwort Wasserstein and at Burrill & Company.
Randy worked for over 15 years at Lehman Brothers, where he completed over 40 advisory transactions in the healthcare and life sciences sectors, ranging in size from $40 million to over $2 billion. He served as Managing Director in the Healthcare Group, Managing Director in the Mergers and Acquisitions Group and as Co-Head of Healthcare Mergers & Acquisitions.
Some of his current and past clients include Barrier Therapeutics, Baxter, Biogen IDEC, Boston Scientific, Bristol-Myers Squibb, Glaxo SmithKline, Merck KGaA, NPS Pharmaceuticals, Pfizer, Teva Pharmaceutical, Schering, Schick Technologies, Thoratec and Versicor.
Mr. Guggenheimer received an AB degree in Economics at Harvard College and earned an MBA from Harvard Business School.
Dr. Van Voorhees has over twenty years of experience in the chemical industry, primarily in investment banking, but also in various corporate development and CFO positions.
His experience includes being the Chief Financial Officer of American Pacific (a public company producing pharmaceutical intermediates and energetic chemicals) and Chief Financial Officer of Research Frontier (a public company licensing light control glass technology) and was involved in capital raising, M&A and business development. His investment banking experience prior to Young & Partners included serving as an Executive Director in Investment Banking at PaineWebber/UBS Warburg and, prior to that, as a Vice President at Wasserstein Perella. His investment banking career has been focused on serving clients in the chemical and advanced materials industries and he has been involved in a broad range of projects, including acquisitions, divestitures, spinoffs, defense advisory assignments and the issuance of private equity and public debt.
Prior to becoming an investment banker, Dr. Van Voorhees served as a Business Manager for AlliedSignal where he was responsible for the Silane Specialties business unit and in corporate development positions at WR Grace and Battelle Memorial Institute.
Dr. Van Voorhees received a Ph.D. in chemistry from the University of Pennsylvania where he focused on precious metal catalyzed reactions. He is also a recipient of an MBA from Columbia University in finance and a BS from SUNY at Stony Brook in chemistry. He has been the author of a number of patents.